Polaris Group engages in the research and development of biotechnology drugs. Its business activities include exploration and confirmation of new drug targets, design and improvement of large and small molecule new drugs, planning and execution of clinical trials, and manufacture and quality control of pharmaceutical drugs. It offers cancer treatment drugs, and contract development and manufacturing organization services for biopharmaceutical industries. The company was founded on February 9, 2006 and is headquartered in Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company